Category
All
New Technology
Service & Software
Internet & Communication
Electronics & Semiconductor
Pharma & Healthcare
Other
Energy & Power
Agriculture
Consumer Goods
Machinery & Equipment
Food & Beverages
Medical Care
Automobile & Transportation
Packaging
Chemical & Material
Medical Devices & Consumables
Category
All
Total: 5 records, 1 pages
Search For: Idiopathic Pulmonary Fibrosis (IPF) Drug
Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
13 Jan 2025
Pharma & Healthcare
Idiopathic Pulmonary Fibrosis (IPF) Drug
According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at US$ 301 million in 2024 and is forecast to a readjusted size of USD 398 million by 2031 with a CAGR of 4.1% during review period.
USD3480.00
Add To Cart
Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2024-2030
29 Feb 2024
Pharma & Healthcare
Idiopathic Pulmonary Fibrosis (IPF) Drug
These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
USD4480.00
Add To Cart
Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
29 Feb 2024
Pharma & Healthcare
Idiopathic Pulmonary Fibrosis (IPF) Drug
These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
USD3480.00
Add To Cart
Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
06 Sep 2023
Pharma & Healthcare
Idiopathic Pulmonary Fibrosis (IPF) Drug
According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at USD 298.4 million in 2022 and is forecast to a readjusted size of USD 393.2 million by 2029 with a CAGR of 4.0% during review period.
USD3480.00
Add To Cart
Global Idiopathic Pulmonary Fibrosis (IPF) Drug Supply, Demand and Key Producers, 2023-2029
06 Sep 2023
Pharma & Healthcare
Idiopathic Pulmonary Fibrosis (IPF) Drug
The global Idiopathic Pulmonary Fibrosis (IPF) Drug market size is expected to reach $ 393.2 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).
USD4480.00
Add To Cart
Popular Product Keywords
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
Insight into the industry market information
Analyze market development needs
Prospects for future development
Develop industry investment strategy
Search For: Idiopathic Pulmonary Fibrosis (IPF) Drug
Total: 5 records, 1 pages
According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at US$ 301 million in 2024 and is forecast to a readjusted size of USD 398 million by 2031 with a CAGR of 4.1% during review period.
USD3480.00
Add To Cart
These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
USD4480.00
Add To Cart
These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.
USD3480.00
Add To Cart
According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at USD 298.4 million in 2022 and is forecast to a readjusted size of USD 393.2 million by 2029 with a CAGR of 4.0% during review period.
USD3480.00
Add To Cart
The global Idiopathic Pulmonary Fibrosis (IPF) Drug market size is expected to reach $ 393.2 million by 2029, rising at a market growth of 4.0% CAGR during the forecast period (2023-2029).
USD4480.00
Add To Cart
Popular Product Keywords
- We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.Speak to our analyst >>
Our Clients
What We Can Provide?
With better results and higher quality products,Our professional reports can achieve four things:
-
Insight into the industry market information
-
Analyze market development needs
-
Prospects for future development
-
Develop industry investment strategy
- Digging deeper into global industry information and providing market strategies.Contact Us >>